➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Boehringer Ingelheim
Baxter
Moodys
Mallinckrodt

Last Updated: July 29, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR STIVARGA

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Stivarga

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01068769 ↗ Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Active, not recruiting Bayer Phase 2 2010-02-01 The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study.
NCT01068769 ↗ Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Active, not recruiting Brigham and Women's Hospital Phase 2 2010-02-01 The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study.
NCT01068769 ↗ Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Active, not recruiting Fox Chase Cancer Center Phase 2 2010-02-01 The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study.
NCT01068769 ↗ Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor Active, not recruiting Massachusetts General Hospital Phase 2 2010-02-01 The purpose of this research study is to determine the safety and activity of regorafenib in participants with advanced gastrointestinal stromal tumor (GIST) if the standard approved therapies, imatinib and sunitinib, have failed to control the disease. Regorafenib is a drug that blocks abnormally active signaling enzymes called "tyrosine kinases" which are important to the growth of GIST. This "tyrosine kinase inhibition" is similar to the way that both imatinib and sunitinib work; however, regorafenib blocks certain additional signaling pathways that are not blocked by imatinib or sunitinib. Regorafenib has been not been tested in GIST participants before this research study.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Stivarga

Condition Name

Condition Name for Stivarga
Intervention Trials
Colorectal Cancer 7
Colorectal Neoplasms 6
Metastatic Colorectal Cancer 6
Stage IVB Colorectal Cancer AJCC v8 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Stivarga
Intervention Trials
Colorectal Neoplasms 27
Adenocarcinoma 9
Gastrointestinal Stromal Tumors 6
Colonic Neoplasms 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Stivarga

Trials by Country

Trials by Country for Stivarga
Location Trials
United States 157
Italy 12
Australia 9
France 8
Japan 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Stivarga
Location Trials
North Carolina 11
Florida 10
California 10
Minnesota 9
Ohio 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Stivarga

Clinical Trial Phase

Clinical Trial Phase for Stivarga
Clinical Trial Phase Trials
Phase 3 3
Phase 2/Phase 3 1
Phase 2 41
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Stivarga
Clinical Trial Phase Trials
Recruiting 40
Not yet recruiting 18
Active, not recruiting 4
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Stivarga

Sponsor Name

Sponsor Name for Stivarga
Sponsor Trials
Bayer 29
National Cancer Institute (NCI) 12
Bristol-Myers Squibb 5
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Stivarga
Sponsor Trials
Other 70
Industry 52
NIH 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Dow
Harvard Business School
Merck
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.